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ABSTRACT
Triple negative breast cancers (TNBCs) account for 15% of all breast cancers, 
and represent one of the most aggressive forms of the disease, exhibiting short 
relapse-free survival. In contrast to other breast cancer subtypes, the absence of 
knowledge about the etiopathogenic alterations that cause TNBCs force the use of 
chemotherapeutics to treat these tumors. Because of this, efforts have been devoted 
with the aim of incorporating novel therapies into the clinical setting. Kinases play 
important roles in the pathophysiology of several tumors, including TNBC. Since 
expression of the MAP kinase ERK5 has been linked to patient outcome in breast 
cancer, we analyzed the potential value of its targeting in TNBC. ERK5 was frequently 
overexpressed and active in samples from patients with TNBC, as well as in explants 
from mice carrying genetically-defined TNBC tumors. Moreover, expression of 
ERK5 was linked to a worse prognosis in TNBC patients. Knockdown experiments 
demonstrated that ERK5 supported proliferation of TNBC cells. Pharmacological 
inhibition of ERK5 with TG02, a clinical stage inhibitor which targets ERK5 and 
other kinases, inhibited cell proliferation by blocking passage of cells through G1 
and G2, and also triggered apoptosis in certain TNBC cell lines. TG02 had significant 
antitumor activity in a TNBC xenograft model in vivo, and also augmented the activity 
of chemotherapeutic agents commonly used to treat TNBC. Together, these data 
indicate that ERK5 targeting may represent a valid strategy against TNBC, and support 
the development of trials aimed at evaluating the clinical effectiveness of drugs that 
block this kinase.
INTRODUCTION
Triple negative breast cancers (TNBCs) account 
for 15% of all breast cancers, and represent one of 
the most aggressive forms of the disease [1]. Despite 
important research efforts aimed at identifying 
molecular alterations in TNBC [2], the lack of known 
etiopathogenic alterations has prevented the development 
of targeted therapeutics in TNBC [3], and force the use of 
chemotherapeutics such as taxanes or vinorelbine for the 
management of TNBC [4, 5].
Kinases play important roles in the pathophysiology 
of several tumors, including TNBC [6]. ERK5 belongs 
to the MAP kinase family of signal transducers [7], and 
its deregulation has been linked to the pathophysiology 
of breast cancer [8]. A recent report has indicated that 
expression of ERK5 in breast tumors is linked to patient 
outcome, since patients with tumors with high levels of 
ERK5 have a poor prognosis as compared to those whose 
tumors do not overexpress ERK5 [9]. In vitro studies have 
shown that ERK5 is a critical mediator of growth factor 
signaling in hormone-receptor positive breast cancer cell 
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lines, and expression of a dominant-negative form of 
ERK5 prevented growth factor-induced proliferation [8]. 
Moreover, in breast cancer cell lines which overexpress 
HER2, ERK5 is constitutively active and inhibition of 
ERK5 causes a decrease in proliferation of HER2+ cells 
[8, 9]. Furthermore, knockdown of ERK5 favored the 
action of drugs commonly used in the treatment of HER2+ 
breast cancer. Therefore, targeting of ERK5 may be of 
therapeutic relevance in those subtypes of breast cancer. 
These precedents raise the question of whether targeting 
ERK5 could be beneficial in the treatment of TNBC.
Here we have analyzed the expression of ERK5 in 
TNBC and the value of its targeting for the therapy of this 
disease. We show that ERK5 expression levels correlate 
with patient outcome in metastatic TNBC. The composite 
analyses of the biochemical, genetic and pharmacologic 
studies carried out in this work suggests that ERK5 
targeting may be beneficial for the therapy of TNBC, and 
open the possibility of clinically testing drugs that act on 
ERK5 for the treatment of patients bearing this type of 
tumors.
RESULTS
ERK5 expression is linked to patient outcome in 
triple negative breast cancer
We evaluated the relationship between ERK5 
expression and patient outcome in specific subsets 
of metastatic (lymph node positive) breast cancer. To 
this end, we used a publicly available database, which 
includes microarray expression data and clinical follow 
up from breast cancer patients [10]. Kaplan-Meier plots 
showed association between ERK5 expression and patient 
outcome in the basal type of breast cancer, which shares 
genomic and pathologic characteristics with TNBC, as 
well as in HER2+ tumors (Figure 1A). In contrast, these 
analyses failed to show any association between ERK5 
expression and patient outcome in metastatic luminal A or 
metastatic luminal B.
The expression of ERK5 protein in tumor samples 
from patients with TNBC, analyzed by Western blot, 
showed that ERK5 was expressed in these samples, 
although at distinct levels (Figure 1B). Comparison 
of ERK5 levels of tumors samples to normal breast 
tissue (BT2561N) showed that ERK5 expression in 
TNBCs was higher than in the normal breast tissue. 
Interestingly, a number of tumor tissue samples contained 
a slower migrating form of ERK5, which corresponds to 
phosphorylated ERK5 (pERK5) [8]. We also explored 
ERK5 levels in tumors derived from mice with genomic 
and pathologic characteristics of TNBCs [11]. Tumors 
from these mice (BT1, BT2, and BT3) also displayed 
elevated levels of ERK5, as compared to non-tumoral 
(NB1, NB2) breast tissue (Figure 1C).
ERK5 knockdown reduces the proliferation of 
triple negative breast cancer cells
The elevated expression of ERK5 in TNBC, 
together with its prognostic relevance, led us to explore 
the value of targeting this kinase as a strategy against this 
type of tumors. For this purpose, we used human TNBC 
cell lines. All the cell lines tested expressed ERK5, and 
some of them contained phosphorylated forms of ERK5 
(Figure 2A). We used knockdown of ERK5 to evaluate 
the impact of reducing its expression on the proliferation 
of TNBC on several of these cell lines. Western blotting 
demonstrated that infection with a shRNA that targets the 
mRNA for ERK5 reduced its protein levels (Figure 2B). 
Knockdown of ERK5 decreased their proliferation (Figure 
2C). Knockdown experiments were also performed on 
HCC1187 cells. These cells proved to be extremely 
sensitive to ERK5 knockdown (Figure S1).
Action of a clinical stage ERK5 inhibitor in 
triple negative breast cancer
The above data suggested that blocking ERK5 
activity may have potential as a therapeutic strategy in 
TNBC. With the aim of translating these findings to the 
clinic, we used TG02, a pyrimidine-based macrocycle with 
ERK5 inhibitory properties [12], which may also target 
other kinases [13]. We selected this compound instead 
of other ERK5 inhibitors [14] because TG02 is the only 
clinical stage ERK5 inhibitor, currently in phase I studies 
(ClinicalTrials.gov Identifier: NCT01204164).
We evaluated the action of TG02 on ERK5 in intact 
TNBC cells. Under resting conditions, ERK5 migrates as 
a 120 kDa protein, and upon activation ERK5 undergoes 
a mobility shift easily detected by Western blotting 
[15]. That mobility shift is caused by phosphorylation 
of ERK5 at its TEY activation domain, as well as by 
phosphorylation of other residues at the C-terminal region 
of ERK5. Phosphorylations at the TEY microdomain are 
due to the ERK5 upstream activation kinase MEK5, while 
phosphorylations at the C-terminus depend on ERK5, 
and are expected to occur by autophosphorylation [16]. 
In MDA-MB231 cells treatment with EGF caused a 
mobility shift of ERK5 (Figure 3A, top panel), indicative 
of activation. Preincubation with TG02 inhibited EGF-
induced ERK5 mobility shift, suggesting that TG02 was 
able to inhibit ERK5 in vivo. To demonstrate that this 
effect of TG02 was not due to inhibition of MEK5, we 
used an antibody which specifically recognizes ERK5 
phosphorylated at its TEY microdomain [8]. Addition 
of EGF resulted in detection of pERK5 by this antibody 
(Figure 3A, middle panel). In cells treated with EGF, 
preincubation with TG02 caused a shift in the mobility of 
ERK5, which migrated faster. Yet ERK5 was recognized 
by the anti-pERK5 antibody, suggesting that the activity 
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Figure 2: ERK5 controls proliferation of TNBC cell lines. (A) Expression of ERK5 in TNBC cell lines. (B) Western blotting 
analyses of ERK5 expression in TNBC cells infected with a shControl or shERK5 lentiviral particles. Expression of GAPDH was used 
as a loading control. (C) Effect of ERK5 knockdown on the proliferation of TNBC cell lines. Cells were infected with lentiviral particles 
including a scrambled control sequence or a sequence targeting ERK5, and the proliferation measured by an MTT assay. Data are represented 
as mean ± SD of quadruplicates.
Figure 1: ERK5 expression is linked to patient outcome in TNBC. (A) Kaplan-Meier analysis of the relationship between ERK5 
expression and patient outcome in the different subgroups of breast cancer. (B) Western blotting analysis of the expression of ERK5 in 
tumors from patients with TNBC (in BT2561, N and T mean normal and tumoral breast tissue, respectively). (C) Expression of ERK5 in 
tumors from Brca1-/p53- mice. NB: normal breast, BT: breast tumor. Expression of GAPDH was used as a loading control and the ratio 
between ERK5 and GAPDH expression was calculated in the tumor samples.
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Figure 3: Effect of TG02 on ERK5 activity and on proliferation of TNBC cells. (A). MDA-MB231 cells were treated with 
EGF (10 nM, 15 minutes) in the absence or presence of TG02 (1 μM, 30 minutes). Cell lysates were immunoprecipitated with anti-ERK5 
and the blots were probed with anti-ERK5 (top blot) or anti-pERK5 (middle blot). Expression of GAPDH was used as a loading control 
(bottom blot). (B) Effect of TG02 on ERK5 activity. ERK5 was immunoprecipitated from control or EGF-treated MDA-MB231 cells. 
Immunoprecipitated ERK5 was used for the in vitro kinase studies using the indicated concentrations of TG02. (C) Representation of the 
quantitative analysis of the amount of hyperphosphorylated ppERK5-I. (D) Dose-response effect of TG02 on different TNBC cell lines. 
Cells were incubated with increasing concentrations of TG02 for 72 hours and cell viability was analyzed by MTT metabolization. Data are 
represented as mean ± SD of quadruplicates, and results are shown as a percentage of control. (E) In vivo effect of TG02. Mice engrafted 
with MDA-MB231 cells were treated orally and daily with TG02 at a dose of 46.92 mg/kg. The graph represents the mean ± SEM of the 
tumor volumes. Differences in tumor growth between the treated group and the control (vehicle) were evaluated using the non-parametric 
Mann-Whitney U test. The asterisk indicates p<0.05. (F) MDA-MB231 cells were treated for 48 hours with TG02 (40 nM) and taxotere 
(4 nM), vinorelbine (3 nM) or cisplatin (7.5 μM) in monotherapy and in two-drug combinations. Cell viability was analyzed by MTT 
metabolization. The potency of the combination was analyzed with the CalcuSyn software and the combination index (CI) is shown at the 
top of each graph. Data are presented as mean ± SD of quadruplicates and results are shown as a percentage of control.
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of MEK5 was preserved. Together, these data demonstrate 
that TG02 can inhibit ERK5 in live MDA-MB231 cells.
To verify that TG02 directly inhibited ERK5 
activity we settled up a novel in vitro assay based on 
the kinase activity of ERK5 [12]. In this assay, ERK5 is 
used as both the enzyme and the substrate, because of its 
autophosphorylation properties. We used ERK5 isolated 
from non-stimulated as well as EGF-stimulated MDA-
MB231 cells as a source of inactive or active kinase, 
respectively. When active ERK5 immunoprecipitated 
from MDA-MB231 cells treated with EGF was subjected 
to the in vitro assay, an additional shift in its mobility 
was observed, indicative of hyperphosphorylation 
(Figure 3B, lane 4). This supershift of ERK5 is due to 
autophosphorylation, and results in the appearance of two 
different bands which correspond to hyperphosphorylated 
ERK5 forms (ppERK5-I and pERK5-II). In the absence of 
EGF stimulation, immunoprecipitated ERK5 was unable 
to undergo any mobility shift (Figure 3B, lane 3). These 
data indicated that for these in vitro kinase assays ERK5 
required previous in vivo activation. Incubation of active 
ERK5 with TG02 dose-dependently prevented the in vitro 
autophosphorylation of ERK5 (Figure 3B, lanes 5-13). 
Quantitative analyses of the fully hyperphosphorylated 
form (ppERK5-I) indicated that the in vitro inhibitory IC50 
value of TG02 towards ERK5 was 100 nM (Figure 3C).
The action of TG02 was analyzed on eight TNBC 
cell lines. As shown in Figure 3D, growth and/or survival 
were inhibited by TG02 in all the TNBC cell lines. 
IC50 values were lower as incubation times increased 
(Figure S2A and S2B).
We next analysed the in vivo effect of TG02 on 
tumors derived by xenografting MDA-MB231. As shown 
in Figure 3E, treatment of mice injected with MDA-
MB231 cells with TG02 delayed tumor growth.
As most antitumor treatments are based on 
combinations of drugs [17], we explored whether TG02 
favoured the action of drugs used in the therapy of TNBC. 
Drug combinations were performed following the constant 
ratio protocol used in the Chou and Talalay algorithm [18]. 
Figure 3F shows the data for the best combinations as well 
as the combination indices obtained. TG02 synergized 
with conventional anti-TNBC treatments, as indicated by 
combination indices below 1. At the concentrations used 
for these combination experiments, the chemotherapeutic 
agents did not affect ERK5 status in live cells (Figure S2C). 
To evaluate whether these chemotherapeutics could 
directly affect ERK5 activity we performed in vitro kinase 
experiments. None of these treatments affected ERK5 
activity (Figure S2D), neither at the concentrations used 
in the combination experiments (lanes 5-7), nor at much 
higher concentrations (Lanes 9-11). In contrast, TG02, 
used as a control, inhibited ERK5 activity. These results 
led us to conclude that the chemotherapeutic drugs used do 
not inhibit the activity of ERK5.
TG02 delays cell cycle progression
The decrease in MTT metabolization caused by 
TG02 could be due to a decrease in cell proliferation, 
augmented cell death, or both. To analyze this, we carried 
out propidium iodide (PI) staining of MDA-MB231 and 
HCC1187 cells treated with TG02. In MDA-MB231 cells, 
treatment with the drug caused accumulation of the cells in 
the G2/M phase (Figure 4A). The drug also increased the 
subG0 population, particularly in HCC1187, indicative of 
stimulation of cell death. These results indicated that the 
antitumor action of TG02 was complex and involved cell 
cycle and apoptotic mechanisms.
To analyse the effect of TG02 on the cell cycle 
we used synchronization agents that block cell cycle 
progression at different phases, followed by release from 
these blockers in the absence or presence of TG02. For 
these experiments, we used MDA-MB231 on which 
a clear effect of TG02 on the cell cycle was observed 
(Figure 4A).
Synchronization of MDA-MB231 cells at late G1 
by a double thymidine block followed by release in the 
absence or presence of TG02 indicated that progression 
of cells along S phase was unaffected by treatment with 
the drug (Figure 4B). In fact, the PI histograms at 3 and 
6 hours after release of control and TG02-treated cells 
were indistinguishable, and at 6 hours after release most 
of the cells had reached G2/M. In untreated cells, and 
12-24 hours after release, a substantial amount of cells 
had progressed from mitosis into G1. In contrast, TG02-
treated cells suffered a clear delay in their progression 
through the G2/M phase. Biochemically, phosphorylation 
of the mitotic marker histone H3 progressively increased 
in untreated cells (Figure 4C). In contrast, in TG02-treated 
cells phosphorylation of histone H3 was minimal. The 
lack of significant p-Histone H3 increases in cells treated 
with TG02 suggested that the drug impaired entry of cells 
into mitosis, and therefore could be impeding G2→M 
progression. Dephosphorylation of tyrosine 15 of CDK1 
is required for entry into M phase [19]. Phosphorylation 
of this site is under the control of the kinase Wee1 and 
the phosphatase CDC25C. In control cells, pCDK1Tyr15 
levels decreased after 12 hours. At this time, the amount 
of Wee1 was analogous to that present at other chase 
times, indicating that pCDK1Tyr15 dephosphorylation 
likely occurred by increased action of CDC25C. TG02 
caused an accumulation of Wee1 (Figure 4C) and inhibited 
pCDK1Tyr15 dephosphorylation, which is indicative of 
CDK1/cyclin B complex inactivity.
To analyze whether TG02 also affects the transition 
through G1, MDA-MB231 cells were synchronized in 
mitosis with nocodazole, and then released in the absence 
or presence of TG02. Cell cycle profiles (Figure 4D) 
as well as phosphorylation of histone H3 (Figure 4E) 
confirmed that MDA-MB231 cells were arrested in mitosis 
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Figure 4: TG02 alters cell cycle progression. (A) MDA-MB231 and HCC1187 cells were incubated with TG02 (1 µM for 24 hours), 
and the cell cycle profile was examined by flow cytometry. (B-E) MDA-MB231 cells were synchronized at late G1 by a double thymidine 
block (B, C) or in mitosis with nocodazole (D, E), followed by release in the absence or presence of TG02 (100 nM). Cell cycle profiles 
were analyzed by FACS (B, D). Protein extracts (C, E) were collected at different times after release, and proteins involved in cell cycle 
progression were analyzed by Western blot.
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after nocodazole blockade. TG02 did not substantially 
affect exit from mitosis, since 3 hours after release most 
of the cells had progressed into the G1 phase (Figure 4D). 
These results are in accordance with the data mentioned 
above indicating that TG02 acted on a step previous to 
the nocodazole-affected checkpoint. However, treatment 
with TG02 profoundly influenced the capability of MDA-
MB231 cells to progress through the G1 phase into the 
S phase as demonstrated by comparison of the cell cycle 
profiles, particularly at 12 and 15 hours after release. 
Progression through the G1 phase requires the coordinate 
and sequential activation of several cyclin/CDK complexes 
[19]. Cyclins D1 and D3 in concert with CDK4/CDK6 
act early in G1, and their activity is commonly detected 
by changes in Rb phosphorylation [20]. This facilitates 
the expression of other proteins involved in G1/S phase 
transition such as cyclin A, needed to activate CDK2 [21]. 
pRbSer780 and pRbSer807/811 levels decreased in cells treated 
with TG02 (Figure 4E). The gradual dephosphorylation 
of pRb in cells treated with TG02 could be responsible 
for the inhibition of cyclin A increase in expression, as 
compared with untreated MDA-MB231 cells.
Effect of TG02 on apoptosis
To analyse the mechanisms of apoptotic cell death 
triggered by TG02 we used HCC1187 cells. In this cell line 
TG02 had a more marked proapoptotic effect, assessed by 
propidium iodide staining and DNA laddering, as compared 
to MDA-MB231 (Figure 5A and Figure S3). Mitochondria 
play an important role in the induction of apoptosis through 
the release of apoptotic mediators that follows increased 
permeability of the outer mitochondrial membrane [22]. To 
investigate whether TG02 altered mitochondrial integrity 
we analyzed mitochondrial membrane potential (∆Ψm). 
Analysis by flow cytometry with TMRE revealed that TG02 
provoked a progressive decrease in ∆Ψm (Figure 5A).
Proteins of the BCL2 family act as major regulators 
of the mitochondrial outer membrane permeability [22]. 
TG02 decreased the levels of the antiapoptotic proteins 
MCL1 and BCL2 (Figure 5B). Moreover, treatment with 
TG02 provoked cleavage of the proapoptotic BCL2 family 
member BID, which may facilitate permeabilization of the 
outer mitochondrial membrane. To check if TG02 induced 
release of proapoptotic mediators from the mitochondrial 
intermembrane space, we carried out subcellular 
fractionation of HCC1187 cells. Cytochrome C along with 
the cytoplasmic protein Apaf-1 and pro-caspase 9 form the 
apoptosome, a macromolecular complex that causes the 
activation of effector caspase 3 [22]. As shown in Figure 
5C, the amount of cytochrome C in mitochondria decreased 
after treatment with TG02, and an ensuing accumulation in 
the cytosol was observed. TG02 also decreased AIF and 
Endo G expression in the mitochondrial fraction. These two 
proteins are known to trigger apoptosis through  caspase-
independent mechanisms. In addition, TG02 treatment 
caused release of SMAC/DIABLO from the mitochondria. 
This protein acts as an inhibitor of the Inhibitor of 
Apoptosis (IAP) family of proteins [22], which were also 
down-regulated by TG02 in HCC1187 cells (Figure 5B).
The release of cytochrome C from the mitochondria 
to the cytosol suggested that caspases could contribute to 
TG02-induced cell death. Treatment with TG02 provoked 
fragmentation of caspases 8, 7, 9 and 3 (Figure 5B). In 
addition, cleavage of the caspase substrate PARP-1 was also 
observed in cells treated with TG02. The involvement of 
caspases in the death process induced by TG02 was further 
analyzed using the pancaspase inhibitor Z-VAD-FMK. 
HCC1187 cells were preincubated for 60 minutes with 
the caspase inhibitor Z-VAD-FMK and then treated with 
TG02. FACS analyses showed that Z-VAD-FMK partially 
inhibited TG02-induced death (Figure 5D), indicating that a 
proportion of the observed cell death was caspase-dependent.
DISCUSSION
In this report, we show that ERK5 levels are 
frequently elevated in tumors from patients with TNBC. 
Furthermore, a relationship was found between high levels 
of ERK5 and worse prognosis in metastatic TNBC. In 
addition, we show that tumors from mice engineered to 
develop TNBC-like tumors also express elevated levels of 
ERK5 as compared to normal breast from the same mice. 
These data provided a springboard for further studies to 
determine the potential of ERK5 targeting in TNBC.
Experiments in which ERK5 was knocked down 
suggested that ERK5 targeting may be beneficial in 
TNBC, prompting us to evaluate the anti-TNBC activity 
of the clinical-stage inhibitor TG02. That drug decreased 
MTT metabolization of all of the TNBC lines tested at 
pharmacologically-achievable concentrations. Moreover, 
TG02 reduced tumor growth in vivo, and synergized 
with standard-of-care drugs used in the TNBC clinic, 
supporting the concept that TG02 may offer clinical 
benefit in this underserved cancer. Furthermore, since 
kinase addition appears to be a characteristic of tumors 
[23-25], agents such as TG02 which act on multiple 
kinases may be considered to expand the antitumoral 
therapeutic armamentarium.
The mechanisms behind cell death triggered by TG02 
are likely to be multifactorial. TG02 provoked a delay in 
cell cycle progression and stimulated cell death. In MDA-
MB231 cells, synchronization experiments indicated that 
treatment with the drug caused a delay in G1→S and G2→M 
transitions. ERK5 has been implicated in the regulation of 
G1→S [15, 26] and G2→M [14, 27] transitions, and this 
suggests that the action of TG02 on the cell cycle may rely, 
at least in part, on its ERK5-inhibitory properties. However, 
while ERK5 may influence cell cycle progression by 
regulating some cyclin/CDK complexes [26], a direct effect 
of TG02 on CDKs [13] cannot be excluded, and probably 
adds to the ERK5-dependent cell cycle regulatory properties.
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Figure 5: TG02 triggers apoptosis through caspase-dependent and independent pathways. (A) HCC1187 cells were treated 
with TG02 (1 µM) for different times (0, 6, 12 and 24 hours). Loss of mitochondrial membrane potential and viability were analyzed 
by flow cytometry after staining with TMRE or propidium iodide (PI), respectively. (B) Expression of proteins involved in apoptotic 
mechanisms was analyzed by Western blot after treatment of HCC1187 cells with TG02 (1 µM) at the indicated times. GAPDH was used 
as loading control. (C) Release of proteins from the intermembrane space of mitochondria in HCC1187 cells treated for 12 and 24 hours 
with TG02 (1 µM) was analyzed by Western blot after subcellular fractionation. COX IV and ERK1/2 were analyzed as mitochondrial 
and cytosolic markers, respectively. (D) Role of caspases in TG02-induced cell death. Induction of cell death by TG02 was analyzed in 
HCC1187 cells by flow cytometry after 1 hour of pretreatment with the pan-caspase inhibitor Z-VAD-FMK (25 µM), followed by treatment 
with TG02 (1 µM) for 24 hours.
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TG02 activated a proapoptotic program in TNBC 
cells, as evidenced by increases in mitochondrial 
permeability which caused release of cytochrome C, 
SMAC/DIABLO, AIF and endonuclease G into the 
cytoplasm. Release of some of these mediators may be 
responsible for the cleavage and activation of caspases. The 
proapoptotic activity of TG02 is most probably driven by 
down regulation of survival proteins of the BCL2 family. 
TG02 inhibits CDK9 [13] and blockade of CDK9-dependent 
phosphorylation of RNA polymerase II reduces transcription 
rates [28], selectively depleting short-lived survival proteins 
including MCL-1, BCL2 and the IAP2 without altering 
expression of more stable relatives, such as BCLXL. In 
HCC1187 cells, TG02 treatment rapidly induced the 
activation of caspase-dependent cell death, an interpretation 
supported by the ability of the pan-caspase inhibitor Z-VAD-
FMK to delay and partially restrict cell death. However, the 
partial inhibition of cell death using this compound indicated 
that caspase-independent mechanisms may also play a role 
in the action of TG02. In this respect, it is worth noting that 
AIF and endonuclease G may facilitate caspase-independent 
cell death when released from the mitochondria to the 
cytosolic and nuclear compartments [22].
In summary, our data show that ERK5 is frequently 
overexpressed in TNBC. Genetic knockdown studies 
demonstrated that ERK5 participated in the proliferation 
of TNBC cells, and treatment with the inhibitor TG02 had 
an antitumor effect in vitro and in vivo. These results, in 
addition to revealing the relevance of ERK5 in TNBC, open 
the door to the clinical evaluation of TG02 in the breast 
cancer clinic, especially in combination with standard- 
of-care chemotherapies used in the treatment of TNBC.
METHODS
Reagents and antibodies
Cell culture media, sera and penicillin-streptomycin 
were purchased from Invitrogen (Carlsbad, CA). Protein 
A-Sepharose was from GE Healthcare (Uppsala, Sweden). 
Taxotere was from Sigma Chemical (St Louis, MO), 
cisplatin was from Ferrer Farma (Barcelona, Spain), 
vinorelbine was from Pierre Fabre (Castres Cedex, 
France). Z-VAD-FMK and annexin V-FITC were from 
BD BioSciences (San Jose, CA). Other generic chemicals 
were purchased from Sigma Chemical (St. Louis, MO), 
Roche Biochemicals (Mannheim, Germany), or Merck 
(Darmstadt, Germany).
The antibodies utilized in the different Western blot 
analyses were: pCHK1Ser296, pCHK2Tyr68, pH2AXSer139, 
caspase-7, caspase-9, COX IV and CDK9 (Cell Signalling 
Technology, Danvers, MA), GAPDH, PARP, pCDK1Tyr15, 
AIF, BCL2, MCL-1, Wee1 and ERK1/2 (Santa Cruz 
Biotechnology, Santa Cruz, CA); caspase-3, caspase-8, 
BCLXL, XIAP, cIAP1, cIAP2, cytochrome C, SMAC/
DIABLO, cyclin A, pRbSer807/811, pRbSer780 and Bid (BD 
Biosciences, San Jose, CA). Bidt was provided by Dr. Huang 
(Walter and Eliza Hall Institute of Medical Research, 
Australia). Polyclonal antisera which recognized Endo G 
(Serotec, Oxford, UK) and phospho-histone H3 (Millipore, 
Bedford, MA) were used. The anti-ERK5 (C-terminal) and 
anti-ERK5-PRO1(R415) antibodies have been previously 
described [29]. Horseradish peroxidase–conjugated secondary 
antibodies were from Bio-Rad (Hercules, CA, USA).
Patient samples and mice tumors
Analyses of the relationship between ERK5 and 
patient outcome was carried out using publicly available 
database, which allows estimation of the relevance of gene 
expression and clinical outcome in breast cancer (http://
www.kmplot.com). TNBC samples from 14 patients were 
obtained from the Pathology Department of the University 
Hospital of Salamanca (Salamanca, Spain). Usage of these 
samples was approved by the Institutional Review Board 
Ethics Committee on Human Research of the Salamanca 
University Hospital.
Tumor samples from mice were obtained after 
sacrifice of the animals and immediately frozen in 
liquid Nitrogen. The Brca1/p53 conditional mice were 
generously provided by Dr. J. Jonkers (Netherlands Cancer 
Institute, Amsterdam). Mice were manipulated at the 
animal facility following legal and institutional guidelines.
For the detection of ERK5 expression by Western 
blot, the tumors were processed as previously described 
[9], and 1 mg of protein was immunoprecipitated with an 
anti-ERK5 antibody. As a control we used tissue derived 
from an area of normal breast tissue from patient BT2561 
and normal breast tissue from mice.
Cell culture, Western blotting and 
immunoprecipitation
The different TNBC cell lines used in this study were 
cultured in DMEM (Dulbecco’s Modified Eagle Medium) 
containing high glucose (4.5 g/L), L-glutamine 4 mM and 
L-pyruvate 5 mM. The medium was supplemented with 
penicillin and streptomycin (100 U/ml and 100 µg/ml, 
respectively) and 5-10% FBS according to cell type. Cells 
were synchronized in mitosis with nocodazole for 14 hours 
or in late G1 with thymidine for 24 hours [30]. Production 
of lentivirus and lentiviral transduction assays, as well 
as analyses of proliferation, cell cycle, and apoptosis 
were performed as described [30]. Western blotting and 
immunoprecipitation were carried out as described [31].
In vitro kinase assay
MDA-MB2321 cells treated with or without EGF 
(10 nM, 15 min) were collected and lysed in ice-cold lysis 
buffer; 1 mg of protein extract was immunoprecipitated 
with the anti-ERK5-PRO1(R415) antibody at 4°C for 
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at least 2 h, and the immune complexes were recovered 
by a short centrifugation, followed by three washes with 
1 ml of cold lysis buffer and two washes with 1 ml of 
kinase buffer (20 mM HEPES, pH 7.6; 20 mM MgCl2; 
25 mM β-glycerophosphate). The immunoprecipitates 
were then incubated with different concentrations of TG02 
(10-10 000 nM) for 1 hour at room temperature and after 
this time ATP and sodium orthovanadate were added to 
a final concentration of 100 μM and kinase reaction was 
performed at 30ºC for 30 min. Samples were analyzed 
by Western blotting with the anti-ERK5 (C-terminal) 
antibody and the ERK5 activity plotted in a graphic as a 
percent of control (maximum activity).
In vivo studies
For the in vivo analyses, 9-10 week old nu/nu 
mice (Harlan Sprague Dawley, Inc. Indianapolis, IN) 
were subcutaneously inoculated into the right flank with 
5 x 106 MDA-MB231 cells and when tumors reached a 
size of 80-120 mm3, mice were randomized in two groups: 
Group 1 (control group that received the vehicle alone); 
and Group 2 (TG02 46.92 mg/kg orally every day). Tumor 
growth was evaluated twice a week and animals were 
euthanized when their tumors reached 1,500 mm3.
Statistical analyses were performed with the 
program SPSS-17.0 (SPSS Inc. Chicago, IL), and 
statistical significance was defined as p<0.05. All animal 
experiments were performed according to the protocols 
approved by the Charles River.
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